Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

Paris, FRANCE – December 5th 2023 – Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures. This infusion of capital, supported by new investor Bpifrance (through its InnoBio 2 fund), and existing backers Khosla Ventures and Seventure Partners (with Health For Life Capital™), propels Eligo towards becoming a clinical-stage biotech. Concurrent with this financing, Laia Crespo, Ph.D., Partner at Sanofi Venture and Benoit Barteau, Investment Director at Bpifrance will join the board of directors.

• Financing led by Sanofi Ventures with participation from new investor Bpifrance (through its InnoBio 2 fund), and existing investors Khosla Ventures and Seventure Partners.
• Funding expected to generate proof of concept clinical data in patients.

Read the PR here.

Tags

ArticleNewsPress Release ServiceEligo Bioscience